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Views and reviews
Congenital musCular dystrophy
Part II: a review of pathogenesis and therapeutic perspectives
Umbertina Conti Reed1
abstract – The congenital muscular dystrophies (CMDs) are a group of genetically and clinically heterogeneous 
hereditary myopathies with preferentially autosomal recessive inheritance, that are characterized by congenital 
hypotonia, delayed motor development and early onset of progressive muscle weakness associated with 
dystrophic pattern on muscle biopsy. The clinical course is broadly variable and can comprise the involvement 
of the brain and eyes. From 1994, a great development in the knowledge of the molecular basis has occurred 
and the classification of CMDs has to be continuously up dated. In the last number of this journal, we presented 
the main clinical and diagnostic data concerning the different subtypes of CMD. In this second part of the 
review, we analyse the main reports from the literature concerning the pathogenesis and the therapeutic 
perspectives of the most common subtypes of CMD: MDC1A with merosin deficiency, collagen VI related CMDs 
(Ullrich and Bethlem), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-
eye-brain disease, Walker Warburg syndrome, MDC1C, MDC1D), and rigid spine syndrome, another much rare 
subtype of CMDs not related with the dystrophin/glycoproteins/extracellular matrix complex. 
Key WorDs: congenital muscular dystrophy, MDC1A, collagen VI related disorders, glycosylation of alpha-
dystroglycan, Fukuyama DMC, muscle-eye-brain (MeB) disease, Walker-Warburg syndrome, rigid spine 
syndrome.
distrofia muscular congênita. parte ii: revisão da patogênese e perspectivas terapêuticas
resumo – As distrofias musculares congênitas (DMCs) são miopatias hereditárias geralmente, porém não 
exclusivamente, de herança autossômica recessiva, que apresentam grande heterogeneidade genética e clínica. 
são caracterizadas por hipotonia muscular congênita, atraso do desenvolvimento motor e fraqueza muscular 
de início precoce associada a padrão distrófico na biópsia muscular. o quadro clínico, de gravidade variável, 
pode também incluir anormalidades oculares e do sistema nervoso central. A partir de 1994, os conhecimentos 
sobre genética e biologia molecular das DMCs progrediram rapidamente, sendo a classificação continuamente 
atualizada. os aspectos clínicos e diagnósticos dos principais subtipos de DMC foram apresentados no 
número anterior deste periódico, como primeira parte desta revisão. Nesta segunda parte apresentaremos os 
principais mecanismos patogênicos e as perspectivas terapêuticas dos subtipos mais comuns de DMC: DMC 
tipo 1A com deficiência de merosina, DMCs relacionadas com alterações do colágeno VI (Ullrich e Bethlem), 
e DMCs com anormalidades de glicosilação da alfa-distroglicana (DMC Fukuyama, DMC “Muscle-eye-brain” 
ou MeB, síndrome de Walker Warburg, DMC tipo 1C, DMC tipo 1D). A DMC com espinha rígida, mais rara e não 
relacionada com alterações do complexo distrofina-glicoproteínas associadas-matriz extracelular também 
será abordada quanto aos mesmos aspectos patogênicos e terapêuticos. 
PAlAVrAs-ChAVes: distrofia muscular congênita, merosina, colágeno VI, glicosilação da alfa-distroglicana, 
DMC Fukuyama, DMC “muscle-eye-brain”-MeB, síndrome de Walker-Warburg, espinha rígida.
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The congenital muscular dystrophies (CMDs) are ge-
netically and clinically heterogeneous hereditary myop-
athies with a predominant autosomal recessive mode of 
inheritance that are characterized by congenital hypoto-
nia, delayed motor development and early onset of pro-
gressive muscle weakness, as well as dystrophic pattern on 
muscle biopsy. The clinical course is broadly variable and 
can comprise the involvement of the brain and eyes1-7. 
From 1994 and mostly in the first years of the cur-
rent century a great input in the knowledge of the mo-
lecular basis has occurred, and the classification of 
CMDs has to be continuously up dated. The official jour-
nal of the World Muscular society, Neuromuscular Dis-
orders, periodically publishes the revised classification 
(Table 1)8. A computerized version of the classification 
is accessible at http://www.musclegenetable.org and 
http://194.167.35.195/. Most of the different genes in-
volved with the pathogenesis of the CMD subtypes are 
related to the function of the dystrophin-glycoproteins 
associated complex (DGC) in the sarcolemma and extra-
cellular matrix and their mutations lead either to defects 
in the glycosylation of alpha-dystroglycan (alpha-dystro-
glycanopathies) or to abnormalities of extracellular ma-
trix proteins (MDC1A and collagen VI related disorders)1-7. 
A fourth subtype, rigid spine CMD, is related to a defect 
of an endoplasmic reticulum protein, selenoprotein N9, 
and recently a new subtype10 was associated to a defect 
of a nuclear protein, lamin A/C.
last month, the first part of this review focused on 
the clinical and diagnostic aspects of the different sub-
types of CMD. Presently, the second part emphasizes the 
main data on pathogenesis and therapeutic perspectives 
for the most common subtypes of CMD, i.e. MDC1A, col-
lagen VI related disorders, CMDs caused by defects of gly-
cosylation of alpha-DG, and finally the much rarer rig-
id spine CMD. 
Before reviewing the essential pathogenic data about 
the most common subtypes of CMD, we summarize the 
general aspects of the organization of the DGC and ex-
tracellular matrix. 
dystrophin-glyCoproteins assoCiated
Complex and extraCellular matrix: general
remarks on struCture and funCtion
The DGC is an assembly of proteins spanning the sar-
colemma of skeletal muscle fibers that forms a chain of 
links between the contractile actin in the cytoskeleton 
and the extracellular matrix11,12 (Fig 1). Defects in the DGC 
can disrupt these links and alter the basement membrane 
organization, resulting in sarcolemmal instability and mus-
cle cells apoptose. In addition to the function of stabiliz-
ing the sarcollema, the DCG is also essential in organizing 
molecules involved in cellular signaling12. 
The first component of the chain of links in the inner 
cytoskeleton is dystrophin that through the amino-termi-
nus domain binds to actin and through the carboxyl ter-
Fig 1. Schematic representation of the main proteins involved in congenital muscular dystrophies, their local-
ization and interactions: laminin alpha-2, integrin alpha-7, collagen VI, alpha-dystroglycan, glycosyltransferases 
POMT1, POMT2, POGnT1, fukutin, FKRP and LARGE, and selenoprotein-N. Reproduced with adaptation from 
Fig.1 of Lisi & Cohn6. Abbreviations: see text; ER: endoplasmic reticulum. 
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Table 1. Classification of congenital muscular dystrophies. Adapted from Gene Table58.
Disease phenotype (inheritance) Gene symbol (chromosome) protein All allelic disease phenotypes - disease symbols
Merosin deficient CMD – (Ar) lAMA2 (6q22–q23)
laminin alpha 2 chain of merosin
Muscular dystrophy, congenital merosin-deficient - MDC1A
Muscular dystrophy, congenital, due to partial lAMA2 deficiency
CMD with merosin 
deficiency – (Ar)
? – (1q42) Muscular dystrophy, congenital, 1B -MDC1B
CMD and abnormal glycosylation 
of dystroglycan – (Ar)
FKrP (19q13.33)
fukutin-related protein
Muscle-eye-brain disease -MeB
Muscular dystrophy, congenital, 1C -MDC1C
Muscular dystrophy, limb-girdle, type 2I -lGMD2I
Walker-Warburg syndrome -WWs3
CMD and abnormal glycosylation 
of dystroglycan – (Ar)
lArGe (22q12.3–q13.1)
like-glycosyltransferase
Muscular dystrophy, congenital, with severe mental retardation -MDC1D
Fukuyama CMD – (Ar) FCMD (9q31–q33)
fukutin
Muscular dystrophy, Fukuyama congenital -FCMD
Muscular dystrophy, limb-girdle, type 2M -lGMD2M
Walker-Warburg syndrome -WWs
Walker-Warburg syndrome – (Ar) FCMD (9q31–q33)
fukutin
Muscular dystrophy, Fukuyama congenital -FCMD
Muscular dystrophy, limb-girdle, type 2M -lGMD2M
Walker-Warburg syndrome -WWs
Walker-Warburg syndrome – (Ar) PoMT1 (9q34.1)
protein-o-mannosyltransferase 1
Muscular dystrophy, limb-girdle, type 2K - lGMD2K
Walker-Warburg syndrome -WWs
Walker-Warburg syndrome – (Ar) PoMT2 (14q24.3)
protein-o-mannosyltransferase 2
Muscle-eye-brain disease -MeB
Walker-Warburg syndrome -WWs2
Walker-Warburg syndrome – (Ar) FKrP (19q13.33)
fukutin-related protein
Muscle-eye-brain disease -MeB
Muscular dystrophy, congenital, 1C -MDC1C
Muscular dystrophy, limb-girdle, type 2I -lGMD2I
Walker-Warburg syndrome -WWs3
Muscle-eye-brain disease – (Ar) PoMGNT1 (1p34.1)
o-linked mannose beta1,2-N-
acetylglucosaminyltransferase
Muscle-eye-brain disease -MeB
Walker-Warburg syndrome -WWs
Muscle-eye-brain disease – (Ar) FKrP (19q13.33)
fukutin-related protein
Muscle-eye-brain disease -MeB
Muscular dystrophy, congenital, 1C -MDC1C
Muscular dystrophy, limb-girdle, type 2I -lGMD2I
Walker-Warburg syndrome -WWs3
Muscle-eye-brain disease – (Ar) PoMT2 (14q24.3)
protein-o-mannosyltransferase 2
Muscle-eye-brain disease -MeB
Walker-Warburg syndrome -WWs2
rigid spine syndrome (rss) – (Ar) sePN1 (1p36.13)
selenoprotein N1
Desmin-related myopathy with Mallory bodies -rsMD1
Minicore myopathy, severe classic form -rsMD1
Muscular dystrophy, rigid spine, 1 -MDrs1
Myopathy, congenital, with fiber-type disproportion -CFTD rss
Ullrich syndrome – (Ar) Col6A1 (21q22.3)
alpha 1 type VI collagen
Bethlem myopathy
ossification of the posterior longitudinal spinal ligaments -oPll
Ullrich congenital muscular dystrophy -UCMD
Ullrich syndrome – (Ar) Col6A2 (21q22.3)
alpha 2 type VI collagen
Bethlem myopathy –
Ullrich scleroatonic muscular dystrophy -UCMD
Ullrich syndrome – (Ar) Col6A3 (2q37)
alpha 3 type VI collagen
Bethlem myopathy –
Ullrich congenital muscular dystrophy -UCMD
Bethlem myopathy – (AD) Col6A1 (21q22.3)
alpha 1 type VI collagen
Bethlem myopathy
ossification of the posterior longitudinal spinal ligaments -oPll –
Ullrich congenital muscular dystrophy -UCMD
Bethlem myopathy – (AD) Col6A3 (2q37)
alpha 3 type VI collagen
Bethlem myopathy –
Ullrich congenital muscular dystrophy -UCMD
Bethlem myopathy – (AD) Col6A2 (21q22.3)
alpha 2 type VI collagen
Bethlem myopathy
Ullrich scleroatonic muscular dystrophy -UCMD -
CMD with integrin 
deficiency – (Ar)
ITGA7 (12q13)
integrin alpha 7 precursor
Myopathy, congenital -ITGA7
AD: autosomal dominant; Ar: autosomal recessive; CMD: congenital muscular dystrophy.
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minus binds to dystroglycan (DG)11,12. Dystrophin changes 
lead to the X-linked Duchenne and Becker muscular dys-
trophies, and are not involved in any type of CMD. The 
following link is dystroglycan (DG) that has two compo-
nents: beta and alpha-DG. Beta-DG is a transmembrane 
glycoprotein and alpha-DG is extracellular but with close 
contact with the peripheral membrane11-13. Both are en-
coded by the same gene and then cleaved into two pro-
teins, alpha and beta11-13. Primary mutations in the gene 
encoding DG have not been reported and the knockout 
mouse for DG is embryonically lethal14. 
Alpha-DG is involved in the next step of the chain of 
links and connects the sarcolemma to the basement mem-
brane. however, for performing this step, alpha-DG needs 
to be glycosylated11-15 (Fig 2). The glycosylation depends on 
the biosynthesis of glycans that occurs by the enzymat-
ic activity of glycosyltransferases, and it is necessary for 
the correct function of many animal proteins, the glyco-
proteins. Dystroglycan glycosylation is highly conserved 
during evolution. The covalently addiction of sugar chains 
(glycans), forming a glycoprotein, induces a modification 
that increases the availability of the protein for ligand in-
teraction with laminin, agrin and perlecan in skeletal mus-
cle, as well as with laminin and neurexin in the brain11-18. 
The glycoproteins act as biosignals for cell-cell communi-
cation, intracellular signaling, protein folding, and target-
ing of proteins within cells11-15. each glycosyltransferase has 
specific expression and localization in tissues or cell type 
as well as along the different stages of development, and 
its specificity is determined by the type of glycan compo-
nent. The most common type of glycosylation that occurs 
in mammals’ proteins is by N-glycan linkage. however, in a 
limited number of glycoproteins of brain, nerve, and skel-
etal muscle, including alpha-DG, the glycosylation is by 
o-glycan linkage and is named o-mannosyl-glycosylation 
because mannosylglycans are the specific sugars that pro-
mote the interaction between alpha-DG and extracellu-
lar matrix ligands. The glycosylation pattern of alpha-DG 
is specific not only for different tissues but also for dif-
ferent regions of the muscle fiber, such as the sarcolem-
ma and the neuromuscular junction15. Protein o-mannose 
beta-1,2-N-acetylglucosaminyltransferase (PoMGnT1) that 
was isolated in 200116, is the first human glycosyltrans-
ferase which was found to participate in o-mannosyl gly-
can synthesis in muscle and brain by adding N-acetylg-
lucosamine to O-linked mannose16. soon after, Michele 
et al.17 and Moore et al.18 suggested that, in addition to 
PoMGnT1, fukutin and acetylglucosaminyltransferase-like 
protein (lArGe) may participate in a similar pathway “that 
ultimately results in transfers of sugar to dystroglycan”. 
In patients with FCMD or MeB disease and in dystrophic 
mice they demonstrated that the o-glycosylation of al-
pha-DG, mediated by different glycosyltransferases, is es-
sential for muscle and brain development and functions. 
During the o-linked mannose glycosilation the glycosyl-
transferases add different glycans directly to the hydrox-
Fig 2. (A) Glycosylation of alpha-DG in normal muscle: glycans attached to alpha-DG link the dystrophin-gly-
coproteins complex to the extracellular matrix (agrin, neurexin, and laminin-alpha 2. (B) Loss of glycosyla-
tion of alpha-DG in the dystrophic alpha-dystroglycanopathies impedes the link with the extracellular ma-
trix. Reproduced from Muntoni et al.36.
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yl groups of alpha-DG on either serine or threonine resi-
dues, following successive steps19. In this way, alpha-DG is 
sequentially modified by glycosyltransferases during the 
transportation from the rough endoplasmic reticulum to 
the trans-Golgi network20. Protein o-mannosyl tranferase 
1 (PoMT1) and protein o-mannosyl tranferase 2 (PoMT2) 
act in endoplasmic reticulum during the first step of the 
o-mannosyl glycan synthesis21, and PoMGnT1 acts during 
the second step in the Golgi apparatus16. PoMT1 transfers 
a mannosyl residue from dolichyl phosphate mannose to 
a serine or threonine residue in alpha-DG, and PoMGnT1 
adds an N-acetylglucosamine residue16. Co-expression of 
PoMT1 and PoMT2 is necessary for O-mannosyltrans-
ferase activity within the er of mammalian cells21. how-
ever, it is still unclear whether these glycans are directly 
involved in ligand binding or play some other role. Fuku-
tin and FKrP are putative glycosyltransferases and their 
exact function and localization are controversial. Initial-
ly, it seemed that fukutin acted in the cis-Golgi compart-
ment, while FKrP probably acted in the rough endoplas-
mic reticulum. Matsumoto et al.22 analysed the precise 
localization of fukutin and FKrP in muscle cells and sug-
gested that FKrP localizes in the rough endoplasmic re-
ticulum and with PoMT1 may play a role in the first O-
mannosylation step of α-DG. others reported that FKrP 
and fukutin are localized subcellularly in the medial-Gol-
gi apparatus23,24 but that the mutations in the FKrP gene 
would lead to endoplasmic reticulum retention and con-
sequent diminution in the Golgi apparatus24. According 
to yamamoto et al.25, although the functions of fukutin 
continue unclear, it seems to interact with alpha-DG dur-
ing glycosylation but binding to the core area of alpha-
DG instead of its sugar chain. Also concerning FKrP, it has 
recently been supposed that in normal and mutant mice 
it is detected in the sarcollema and coexists with DG in 
the native dystrophin-glycoprotein complex, perhaps hav-
ing its localization mediated by DG26. It has not yet been 
demonstrated that lArGe is a glycosyltransferase itself 
but the Kanagawa et al.27 found that alpha-DG interacts 
with lArGe at two different domains, one involved with 
the glycosilation process itself and the other at intrac-
ellular level (N-terminal domain of α-DG) for defining a 
recognition motif necessary to initiate functional glyco-
sylation. Therefore, in order to stimulate alpha-DG hy-
perglycosylation lArGe needs to both physically inter-
act with alpha-DG intracellularly and function as a glyco-
syltransferase28. The two interactions are essential for the 
occurrence of the link between alpha-DG and laminin as 
well as other extracellular matrix ligands. lArGe also in-
teracts with a homologous glycosyltransferase (glycosyl-
transferase-like 1B-GylTl1B) named lArGe2 that is highly 
similar and also localizes to the Golgi apparatus but has 
lesser tissue expression and has not been detected in mus-
cle and brain29. It is supposed that also lArGe2 is involved 
in alpha-DG glycosylation and that both show functional 
integration29. Although it has not yet been demonstrated 
that lArGe and lArGe 2 are glycosyltransferases them-
selves, their overexpression in cultured cells induce al-
pha-DG hyperglycosilation and laminin-binding; therefore, 
this biological activity in vivo suggests that both act as 
glycosyltransferases30. Indeed, lArGe2 was found to sup-
port the maturation of alpha-dystroglycan more effec-
tively than lArGe31.
The structure, biosynthesis, and pathology of o-man-
nosyl glycans have been described in details by endo13,15,32,33, 
Barresi and Campbell34 and Martin35. It is still under analy-
ses whether these glycans are directly involved in ligand 
binding or play some other role30.
Molecular changes in genes that codified glycosyl-
transferases affecting this step of the DAG chain of links 
are responsible for the pathogenesis of five CMDs named 
alpha-dystroglycanopathies or CMDs by defects of the o-
mannosyl-glycosylation of alpha-DG1-7,15,30,33,36-50: Fukuyama 
CMD (FCMD), “muscle-eye-brain” (MeB) disease, Walker-
Warburg syndrome (WWs), MDC1C and MCD1D. 
After being glycosylated alpha-DG links to the follow-
ing component of the DAG chain, laminin alpha-2, a gly-
coprotein that together with collagen IV is a major con-
stituent of the basement membrane of the extracellular 
matrix51 (Fig. 1). Its linkage to alpha-DG was firstly demon-
strated by Ibraghimov-Beskrovnaya51 All the components 
of the laminin family are essential for the assembly and 
architectural integrity of the mammals’ basement mem-
branes52. The molecule of laminin is a heterotimer com-
posed of three chains, alpha, beta e gamma, whose spa-
tial arrangement has the form of a cross. The long arm of 
the cross corresponds to the long arms of the three chains 
closely assembled and each one of the three short arms of 
the cross comes from a different chain. At the moment 16 
laminin isoforms are known, each one formed by a specific 
combination of alpha, beta, and gamma chain that allows 
a broad capacity of interaction with cellular receptors 
such as integrins and other extracellular ligands. Differ-
ent laminins have their own spatial and temporal expres-
sion. In a recent review on the role of laminins in physio-
logical and pathogenic conditions, schéele et al.53 report-
ed that one of the specific basement membrane functions 
is “to govern cell fate by inducing intracellular signalling 
cascades”. In fact the broad spatial distribution of laminin 
genes products offers tissue specificity as each tissue has 
its proper ligands. The temporal expression of laminins 
influences the processes of proliferation, differentiation, 
adhesion, and migration in different stages of normal life 
or in pathologic states52. The role of laminin in the ner-
vous system is less well defined than in the muscle, but its 
adhesive molecule is supposed to have an important role 
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in peripheral nerve regeneration, influencing neurite out-
growth, neural differentiation, and synapse formation54. 
laminin-2 or laminin alpha-2, also named merosin, is a 
heterotrimer composed of alpha-2, beta-1, and gamma-1 
chains, that is specifically found in the basement mem-
branes of striated muscle, schwann cells and placental 
trophoblasts55. Vuolteenaho et al.56 described the com-
plete primary structure of the human laminin M chain 
(merosin), assigned it to 6q22-23 and reported its tecid-
ual distribution, including in human fetal tissues. The 
term merosin was changed to muscle laminin alpha-2 by 
Burgeson et al.57 in 1994. In muscle, laminin alpha-2 acts 
as the most important ligand for the surface receptors 
of the muscular fiber, and is essential for controlling the 
transmission of force from the interior of the cytoskel-
eton. During the myogenesis, laminin alpha-2 is also in-
volved in the stability and survival of the myotubes that 
develop normally in the first stages but collapsed and de-
generated when the mature, contractile function of the 
muscular cell begins58. The biological functions of the rest 
of the chains of laminin complex (alpha-1, alpha-4 and al-
pha-5 chains) include the formation of basement mem-
branes during muscle myogenesis and development, and 
probably a role in signal transmission events during mus-
cle formation and muscle regeneration59. 
Molecular changes in the gene responsible by codify-
ing laminin alpha-2 are the source of the most common 
form of CMD, termed MDC1A or merosin-deficient CMD60. 
In addition to the connection with alpha-DG, laminin al-
pha-2 also connects with the sarcolemma through the gly-
coprotein named integrin, and to the rest of the extracel-
lular matrix network mainly through collagen IV unit (Fig 1).
Integrins are heterodimeric cell adhesion receptors or-
ganized in a transmembrane arrangement and extracellu-
lar domains that organize the cytoskeletand links to the 
extracellular matrix. They constitute the major cell sur-
face receptors allowing cell-extracellular matrix adhe-
sion61. In humans at least 18 alpha and eight beta subunits 
have been identified that compose 24 heterodimers with 
a great diversity of functions and tecidual specificity61,62. 
Playing as adhesion receptors, integrins act in the trans-
duction of signals to the cell interior and receive intrac-
ellular signals that control their own ligand-binding af-
finity. similarly to laminin, through these signaling path-
ways, integrins participate in proliferation, differentiation, 
apoptosis, and cell migration at different developmen-
tal stages61,62. 
The specific integrin for the muscular fibre is integrin 
alpha-7/beta-1 that represents another link between the 
muscle fiber and the extracellular matrix that is indepen-
dent of DG. Mutations in the integrin alpha7 gene are re-
sponsible by a very rare form of CMD63. 
The link with laminin is the last step of the DAG chain 
but in the basement membrane, laminin alpha 2 binds to 
other laminins, nidogen (that binds to collagen IV and per-
lecan), agrin, fibronectin and different macromolecules64. 
In addition to laminin, type IV collagen is the most abun-
dant glycoprotein in the basement membrane and all to-
gether the components of the basement membrane form 
a thin pericellular matrix that is involved in many cellu-
lar functions (gene expression, adhesion, migration, dif-
ferentiation, and apoptosis)64,65. Through its carboxyl-ter-
minal globular domain collagen IV interacts with the ami-
no-terminal domain of the collagen VI alpha-1 chain65 and 
this connection is essential for anchoring the basement 
membrane of the muscular fiber to the other components 
of the extracellular matrix and maintaining the structural 
muscle integrity65-68. Collagen VI provides a microfilamen-
tous network in the extracellular matrix of the muscular 
tissue, as well as in other organs66-68. lampe and Bushby69 
revised the literature concerning the main roles of colla-
gen VI: it also interacts with several extracellular matrix 
components such as other fibrillar collagens, perlecan, 
glycoproteins associated to elastin, proteoglycans and fi-
bronectin. In addition to these mechanical functions it 
also acts in cycle signaling, homeostasis control, tissue de-
velopment and architecture, as well as in repair process-
es such as wound healing69. 
Collagen VI is formed by three chains: alpha-1, alpha-2, 
and alpha-3, each one encoded by a different gene. The 
structure and macromolecular organization of type VI col-
lagen was described by engel et al.66, and later by Baldock 
et al.70 and Ball et al.71 reported in details the biochemical 
basis of the tetrameric and microfibrillar organization. The 
three chains contribute to the formation of a triple heli-
cal monomer: first they associate through the C-terminal 
globular domain and then the triple helix folds from the C 
to N terminus to form the monomer that is the basic col-
lagen VI structure66. The globular amino and carboxi-ter-
minal regions of each monomer are assembled in an an-
tiparallel manner by disulfide bonds into dimers that are 
aligned laterally to form tetramers. each tetramer is thre-
fore made by eight smaller subunits corresponding to the 
globular amino and carboxi-terminal regions of the mo-
nomeric components of the microfibril. The tetramers are 
then secreted and associated end-to-end to form a char-
acteristic microfibrils repeat that constructs a network of 
microfibrils (Fig 3). The formation of monomers, dimers 
and tetramers occurs intracellularly, while the microfibril 
assembly occurs in the extracellular space66,69-71. 
Mutations in the genes that codify the three colla-
gen VI subunits lead to the second most common form 
of CMD, Ullrich atonic-sclerotic CMD72-75 and to Bethlem 
myopathy76,77 that now is included into CMD classification8.
After this brief explanation about the normal struc-
ture of the DAG/extracellular matrix complex we present 
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the main pathogenic aspects and therapeutic perspectives 
of the most common forms of CMD that are caused by 
changes in this complex: CMD with merosin (laminin al-
pha-2) deficiency (MDC1A); collagen type VI related CMDs 
(Ullrich CMD and Bethlem myopathy); CMDs with abnor-
mal glycosylation of alpha-DG (Fukuyama CMD, MeB dis-
ease, WWs, MDC1C, MDC1D). 
Finally, we present the main pathogenic data and ther-
apeutic researches about the much rare rigid spine CMD 
caused by a defect of an endoplasmic reticulum protein, 
selenoprotein N. 
merosin-defiCient Congenital 
musCular dystrophy: mdC1a
Pathogenesis 
MDC1A is caused by mutations in the laminin alpha-2 
gene (lAMA2) and was first described by Tomé et al. in 
199460. In the same year, hillaire et al.78 demonstrated that 
this specific CMD is linked to 6q2, and soon after heib-
ling-leclerc et al.79 found the first homozygous mutations 
in lAMA2 gene in two patients who had been reported 
by Tomé et al.60. The disease has congenital onset and 
progressive course and patients manifest severe muscu-
lar weakness and atrophy, diffuse contractures, inability 
to walk and facial dysmorphism61,2,60. Diffuse low-density 
areas in the cerebral white matter are the hallmark of this 
condition1,2,60. In a few patients who have partial laminin 
alpha-2 deficiency, a later onset and a milder course can 
be observed1,2. on muscle biopsies the dystrophic pat-
tern is marked with fiber size variation, huge interstitial 
proliferation and fatty infiltration1,2,60. Necrosis and re-
generation features are less prominent. Taniguchi et al.80 
showed that regenerative features are less prominent in 
MDC1A and FCMD than in Duchenne muscular dystrophy. 
FCMD and MDC1A muscular samples of patients at differ-
ent stages of life showed increased expression of extracel-
lular matrix genes and downregulation of genes that cod-
ify structural components of mature muscle. This active 
interstitial fibrosis with less active regeneration of muscle 
cell components suggested that FCMD and MDC1A could 
be primary fibrotic diseases80. 
Due to the fact that the alpha-2 subunit of laminin is 
also expressed in the basal lamina of schwann cell-axon 
unit, a peripheral demyelinating neuropathy affecting pre-
dominantly motor fibers81, but also the sensitive ones82, 
is a feature of laminin alpha-2 -deficient CMD. In the dy 
mouse model laminin alpha-2 is expressed in the en-
doneurium surrounding the schwann cell/myelin sheath 
and interacts with dystroglycan and/or alpha 6 beta 4 in-
tegrin located at the outer membrane of schwann cell/
myelin sheath. Its expression influences the peripheral 
myelinogenesis83. however, peripheral motor nerves in-
volvement has not been found in Brazilian children with 
MDC 1A84,85 and this fact might be due to the type and lo-
cation of the mutation84.
The characteristic pattern of white matter abnormal-
ity associated to MDC1A has been extensively analysed. 
opposite to the peripheral nerve, in which laminin alpha 
2 is associated only with myelinated and not with unmy-
elinated nerve fibers and is involved in the myelin stabil-
ity86, a role for laminin alpha-2 in central myelination has 
not been confirmed. Villanova et al.87 found that lamin-
in alpha-2 chain is localized to the basal lamina of all ce-
rebral blood vessels and supposed that it may be impor-
tant for the selective filtration capability of the blood-
brain barrier. In patients with MDC1A the lack of lamin-
in alpha-2 may lead to an abnormality of the blood-brain 
barrier causing impaired selective filtration. Caro et al.88 
postulated that disruption of the blood-brain barrier as-
sociated with laminin alpha-2 leads to increased water 
content, resulting in abnormal white matter signal inten-
sity. Using magnetic resonance spectroscopy and appar-
ent diffusion coefficient mapping, leite et al.89 detected 
abnormally high free-water concentrations in the white 
matter of our Brazilian patients with MDC1A and more 
prominent changes in the parietal, frontal, and tempo-
ral white matter. They also found no correlation between 
the extent of white matter abnormality on MrI and the 
clinical status as well as the degree of laminin alpha-2 de-
ficiency (partial or total). sijens et al.90 in a patient with 
MDC1A observed that the concentrations of all metabo-
lites detected by brain magnetic resonance spectroscopy 
were decreased only in the white matter. This observation 
Fig 3. Partial reproduction of Fig 1 from Baldock et al.114: “a diagram 
showing the assembly of collagen VI microfibrils from the three  al-
pha chains. The formation of monomers, dimers and tetramers oc-
curs intracellularly, while microfibril assembly occurs in the extra-
cellular space”70.
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combined with fractional anisotropy decrease and appar-
ent diffusion coefficient increase in the white matter indi-
cated a presence of vasogenic edema in the white matter. 
The same was concluded by Brockmann et al.91 that ob-
served a metabolite profile suggesting white matter ede-
ma which supports the hypothesis that laminin alpha2 de-
ficiency results in leakage of fluids across the blood-brain 
barrier. Anyway, the pathophysiology of the white matter 
changes is not completely elucidated.
lAMA 2 mutations are markedly variable spanning all 
protein domains92-94 and, in general, the molecular diag-
nosis is not considered a priority in children with MDC1A, 
due to the homogeneous phenotype, the easy immunohis-
tochemical analysis of laminin alpha-2 chain in muscle1,2,60 
and skin95, and the characteristic white matter abnormali-
ties on neuroimaging. however, siala et al.96,97 have empha-
sized the utility of mrNA analysis in cases of MDC 1A to 
understand the mechanism of the mutation and the gen-
otype-phenotype correlation. recently, also oliveira et 
al.98 emphasized the utility of analyzing genotype/phe-
notype correlations in MDC1A. In 26 patients they report-
ed 96% of mutation detection rate using full genomic se-
quencing and complementary DNA analysis. They detect-
ed new polymorphisms and novel nonsense and truncat-
ing mutations, as well as the first fully characterized gross 
deletion. Interestingly, in the two patients with the mild-
er clinical presentation and a partial reduction in muscle 
laminin-alpha2 one of the alleles showed a missense mu-
tation that was not observed in any of the severe cases98.
Therapeutic perspectives
From 1994, knock-out mouse or spontaneous mutant 
mouse strains have been identified as animal models for 
MDC1A with total and partial deficiency99-105, and experi-
mental therapeutic strategies have been attempted102,103,106-
116. In mice, Kuang et al.102,103 were successful in obtaining 
the expression of a human laminin alpha 2 chain trans-
gene under the regulation of a muscle-specific creatine 
kinase promoter. They detected the synthesis of laminin 
alpha-2 in muscle and a marked improvement of the clin-
ical and histopathological changes; however, there was no 
improvement of the peripheral neuropathy and they con-
cluded that potential new therapies have to be also di-
rected to restore laminin alpha-2 in other tissue as CNs 
and peripheral nerves. Vilkin et al.106 studying both human 
and mouse myogenic cells verified that pure muscle cells 
are able to synthesize laminin alpha-2 chain. Using primary 
muscle cell culture transplantation, they found that lami-
nin alpha-2 is secreted and expressed in both non-dystro-
phic muscles of an immunodeficient mouse and dystro-
phic muscles of a CMD animal model. however, not all 
myoblasts or muscle fibers that they form are capable of 
secretion and deposition in vivo as cell spreading and dif-
fusion of the protein remain restricted to the injection 
site. In addition, the success of myoblast transplantation 
depends on future advances for controlling the immune 
response of the receptor and his biochemical adequacy 
with the donor. In dyW/dyW mice a “replacement therapy” 
using a mini-agrin (miniaturized form of agrin) resulted in a 
lesser muscle degeneration and in a decrease of mortality 
that is mediated through the linking of muscle basement 
membrane to the DGC, and not to integrin107. The first at-
tempt of somatic gene therapy to treat mice with laminin 
alpha-2 deficiency was performed by Qiao et al.108. They 
used adeno-associated viral vector for delivering mini-
agrin gene into dyW/dyW mice and obtained an improve-
ment of the dystrophic pattern. Mini-agrin not only ame-
liorates the phenotype in those mice but also decelerates 
disease progression when applied at late stages. Meinen 
et al.109 demonstrated that full-length agrin is also capable 
of promoting this improvement This result indicates the 
role of DG not only in the pathogenesis of CMDs caused 
by hypoglycosilation of alpha-DG, but also in MDC1A. The 
improvement of the phenotype may be due to the link 
between ‘non-muscle’ laminins and DG through miniagrin, 
therefore maintaining the sarcollema stability. These au-
thors109 also supposed that since the genetic manipulation 
in dyW/dyW mice can prevent apoptosis, it might be pos-
sible that antitiapoptotic agents act synergistically with 
mini-agrin. Therefore, a future therapeutic attempt for 
patients with MDC1A could be the combination of anti-
apoptotic drugs with the expression of mini-agrin in mus-
cle, and/or the up-regulation of endogenous agrin. Gaw-
lik et al.110-112 generated laminin alpha-2 deficient mice ex-
pressing laminin alpha-1 in peripheral nerves and muscles. 
Dy3K/dy3K mice harboring the laminin alpha-1 transgene 
in these tissues presented reduced muscular dystrophy 
and show peripheral myelination. The finding that trans-
genically expressed laminin alpha-1compensates the lack 
of laminin alpha-2 in muscles and peripheral nerves indi-
cates that laminin alpha-1 can be an ideal candidate for 
replacing laminin alpha-2 chain in MDC1A112. In addition, 
the authors considered that laminin alpha-1 overexpres-
sion induced by gene therapy would be paralogous, there-
fore minimizing adverse immunological responses. They 
also generated generated dy3k/dy3k laminin-a2 deficient 
mice in which the expression of alpha-DG in muscle is 
increased112. Using transgenic expression of laminin-a1, 
they obtained a restoration of the basement membrane 
and a normalization of alpha-DG hyperexpression, there-
fore demonstrating a probable interaction between lami-
nin-a1 chain and alpha-DG112. laminin-a1 also restored the 
link with the integrin at the sarcollema, what represents 
an additional way for increasing the muscle cell stabili-
ty. hagiwara et al.113 tested bone marrow transplantation 
in laminin-alpha2-deficient (dy) mice and reported an in-
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crease in lifespan, growth rate, muscle strength, and re-
spiratory function. Xu et al.114 demonstrated that embry-
onic or postnatal overexpression of cytotoxic T cell Gal-
NAc transferase (Galgt2) (the latter using adeno-associat-
ed virus) is effective in inhibiting the development of the 
muscular dystrophy or altering the disease progression 
in skeletal muscles of dy(w) by increasing the expression 
of agrin. Fukada et al.115 reported another possible ther-
apeutic strategy for MDC1A. In normal animals, laminin 
alpha-2 is produced in CD90(+) cell fractions (from mes-
enchimal cells) not depending on its fusion with myogen-
ic cells. They demonstrated that the number of C90+cells 
increases during muscle regeneration process in vivo and 
as those cells can be transplanted to the animal model of 
MDC 1A, perhaps they represent a new source of cellular 
theraphy. Allamand et al.116 using drugs that force read-
ing through premature termination codons (PTCs) dem-
onstrated that the mutant mrNAs were strongly stabi-
lized in myotubes derived from MDC1 A after administra-
tion of negamycin but were not able to allow re-expres-
sion of laminin alpha-2, perhaps consequently to transla-
tional or post-translational troubles. They concluded that 
this novel form of therapy requires more studies to de-
fine the nucleotide context of PTCs, the mechanism of 
mrNA stability and its translation into a functional pro-
tein. Finally, the future treatment of lamininopathies may 
include stem-cell approaches as well as gene therapy53.
Collagen Vi related musCle disorders
Pathogenesis
Mutations in each one of the three collagen VI genes, 
Col6A1 (21 q22.3), Col6A2 (21 q22. 3), and Col6A3 (2 q37) 
that encode respectively the alpha-1, alpha-2 and alpha-3 
chains of collagen VI, cause two types of muscle disor-
ders: Bethlem myopathy, with mild or moderate pheno-
type, and Ullrich CMD, with severe phenotype1-4,6,7,69,117. 
Bethlem myopathy is a slowly progressive disorder with 
variable age of onset, congenital or within the first or sec-
ond decade of life, and marked flexion contractures of 
several joints7,69,76,77,117-119. Ullrich CMD is an early onset con-
dition with severe weakness and progressive course that 
manifests proximal joint contractures and marked distal 
hyperlaxity. Protruding calcanei, follicular hyperkeratosis, 
and abnormal scarring are other frequent clinical signs1-4, 
6,7,69,72,73,118,119.
Until few years ago, Bethlem myopathy and Ullrich 
CMD were separate entities with distinct modes of in-
heritance; after the recognition of heterozygous in-frame 
deletions acting in a dominantly-negative way in patients 
with Ullrich phenotype the boundaries between Bethlem 
myopathy and Ullrich CMD became narrow69. According 
to lampe and Bushby69 it is becoming clear that BM and 
UCMD represent opposite end points of a clinical con-
tinuum in which individuals presenting with intermedi-
ate phenotypes could be considered to have either ‘‘mild 
UCMD’’ or ‘‘severe BM’’. The concept of a spectrum of col-
lagen VI-related disorders with marked clinical and genet-
ic heterogeneity has emerged from the recent advances 
on the molecular mechanism of both diseases69. The com-
plex genotype/phenotype correlations that have been 
broadly analysed in these two conditions clearly indicate 
that in both collagen VI-related disorders the main path-
omechanism is due to the disruption of collagen VI an-
chorage to the basal lamina of the muscular fibers74,75,120-138. 
Presently more than 60% of patients with collagen VI 
related disorders have autosomal dominant or recessive 
mutations identified121; however, the highly polymorphic 
nature of the three genes suggests the need of specific 
methods of mutations analysis for performing an adequate 
genetic counseling121. since the triple helical deletions are 
readily detectable by rT-PCr analysis, lampe et al.122 rec-
ommend that mutation analysis checks these regions 
first by rT-PCr prior to screen all the 107 coding exons.
The data from molecular analysis in Bethlem myopa-
thy revealed that Col6A1 is the most involved gene and 
a splice site mutation seems to be the most common, not 
only in Col6A1 as also in Col6A2 and Col6A3 genes123,124. 
The α1exon 14 skipping mutation is the most commonly 
reported in Bethlem patients75,121,123-125, leading to reduced 
amounts of collagen VI protein, some of which is struc-
turally abnormal with an impaired ability to form micro-
fibrils69. As different kinds of mutations have been found, 
the pathogenic mechanism of Bethlem miopathy and the 
degree of clinical severity depend on the effect of the 
mutation on the structure, biosynthesis, secretion and as-
sembly of collagen VI. In patients with different types of 
mutations, many have attempted to interpret the way by 
which the mutation alters the collagen VI organization 
and defines genotype/phenotype correlations. For ex-
ample, a heterozygous nonsense mutation causing an al-
pha-1 premature stop codon and a decrease of available 
alpha-1 chains consequently reduces production and se-
cretion of collagen VI126. otherwise, a heterozygous mis-
sense mutation interrupting the repetitive amino acid se-
quence (glycine mutation) that forms the characteristic 
collagen triple helix either in the alpha-1or alpha-2 chains 
does not affect collagen VI intracellular monomer, dimer, 
and tetramer assembly or secretion, but the mutant te-
tramers are anomalous (kinked) and the extracellular mi-
crofibrils are functionally deficient127. Patients reported 
with a heterozygous in-frame deletion in the triple-heli-
cal domain resulting in exon skipping in the Col6A1 gene 
have either a typical clinical picture with finger contrac-
tures125 or a course more severe than that commonly re-
ported128. some data indicate that large deletions and mu-
tations inside the triple-helical collagen VI monomer he-
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lix formed by alpha-1, 2 and 3 polypeptides are associat-
ed with a phenotype more severe than those mutations 
occurring in the amino-terminal globular region118. Pepe et 
al.129 found two large and highly similar heterozygous Co-
l6A1 genomic deletions, spanning from intron 8 to exon 
13 or intron 13, in two patients, one with Bethlem myopa-
thy and the other with moderate Ullrich CMD. They not-
ed that as a similar deletion had been previously report-
ed in the severe Brazilian case with Ullrich CMD, the pres-
ence of a deletion-prone region involving the minisatellite 
in intron 8 of Col6A1 could be suggested129. 
lampe and Bushby69 summarized the most frequent 
pathogenic mechanisms in Bethlem myopathy: single 
amino acid substitutions disrupting the Gly-Xaa-yaa mo-
tif of the triple helical domain in Col6A1, Col6A2, or 
Col6A377,121,127,130,and splice site mutations75,121,125,128 which 
cause skipping of Col6A1 exon 14 during pre-mrNA splic-
ing and consequently in-frame deletion of 18 amino acids 
from the triple helical domain of the a1 chain. In the first 
case, mutations towards the N terminal region of the tri-
ple helix may cause kinking of the tetramers in the nor-
mally straight supercoiled triple helical region, thus re-
ducing their ability to form microfibrils127 and exerting a 
dominant negative effect. Baker et al.124 confirmed that 
the majority of the Bethlem myopathy mutations occur 
toward the N-terminal end of the triple helix, that is a 
critical region of the collagen VI monomer (α1:α2:α3) is 
critical for efficient dimer, tetramer, and microfibril as-
sembly. however, in the second case, the interpretation 
of the influence of missplicing mutations on collagen VI 
organization is difficult and needs caution69.
recently, in one patient with Bethlem myopathy it was 
described a novel mutation that apparently did not affect 
the assembly, and it was suggested that its effect could 
be influencing collagen VI interactions in the extracellu-
lar matrix124.
In relation to Ullrich phenotype, the initial molecu-
lar studies in Col6A2 and Col6A3 genes pointed only to 
recessive mutations73,74,118. lampe and Bushby69 revised the 
literature about the type of mutations in Ullrich CMD and 
reported a large number of the mutations that introduce 
premature termination codons with consequent nonsense 
mediated mrNA decay and loss of the mutated chain; an-
other common type of mutation is by splicing that leads 
to in-frame exonic deletions as well as in-frame genom-
ic deletions. Different missense changes can also occur 
within the triple helical and C terminal domains of Co-
l6A2 and the N-terminal domains of Col6A3 their inter-
pretation is difficult. 
In 2003, the first heterozygous in-frame deletions act-
ing in a dominantly-negative way was found in the Co-
l6A1 gene75 in one Brazilian patient with severe Ullrich 
phenotype131; soon, more patients with a dominantly act-
ing mutation in the Col6A1 were reported132-134, and finally 
this same type of mutation has also been found in Ullrich 
patients with mutations in Col6A2 and Col6A3 genes132. 
heterozygously occurring N-terminal triple helical in-
frame deletions allow mutant monomers to form dimers 
but secreted tetramers are abnormal with a consequent 
dominant negative effect on microfibrillar assembly132. In 
general, the complete absence of collagen VI in the extra-
cellular matrix depends on mutations that exert a strong 
dominant-negative effect and compromise intracellular 
assembly of dimers, tetramers, and extracellular micro-
fibrils132. however, the pathogenic effect of the in-frame 
heterozygous deletions is still poorly understood and the 
genetic counselling of patients and their families is a diffi-
cult task, as it has been also demonstrated by Peat et al.135.
Pace et al.136 recently considered that in spite of the 
great number of different types of mutations that have 
been already identified detailed analyses of the effects 
of the mutations on assembly of the protein have been 
conducted only in a small number of patients75,124,125,127,132. 
Pace et al.136 investigated in eight patients the mechanism 
by which different dominant glycine mutations in the col-
lagen VI triple helix produce a spectrum of clinical phe-
notypes from mild Bethlem myopathy to severe UCMD, 
therefore pointing to the fact that the collagen VI relat-
ed disorders form a continuum of clinical severity. Their 
study136 identified that in both, Bethlem and Ullrich CMD, 
heterozygous glycine mutations toward the N-terminal 
end of the triple helix impair the collagen VI assembly in 
two different ways, therefore producing different pheno-
types: in the first that correspond to less compromised 
patients, collagen VI dimers accumulated in the cell but 
microfibril formation in the medium is moderately re-
duced, with no significant collagen VI decrease in the ex-
tracellular matrix; in the second, that corresponds to se-
verely affected Ullrich patients, the assembly defects are 
more pronounced, some secreted collagen VI tetramers 
are not disulfide bonded, microfibril formation in the me-
dium is altered, and collagen VI is decreased in the extra-
cellular matrix136. Pace et al.136 supposed that the relative 
positions of the mutations contribute to understand why 
some glycine mutations in this region have no detectable 
effect on disulfide bonding whereas others result in se-
cretion of nondisulfide bonded tetramers. In conclusion, 
they demonstrated that in patients with different domi-
nant glycine mutations a mild phenotype is associated to 
a mild assembly defect whereas severe assembly defects 
result in moderate-to-severe phenotype. 
okada et al.138 found that in Japanese population mu-
tations in collagen VI genes can lead to a collagen VI de-
ficiency in the sarcollema (where normally it is strongly 
delineated) but with apparently normal amount in the in-
terstitium. They sequenced the three collagen VI genes in 
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26 Japanese patients with primary collagen VI deficiency 
that in Japan accounts for 7.2% of CMD cases. By immu-
nohistochemical analysis they found that most patients 
had sarcolemma-specific collagen VI deficiency and five 
had complete collagen VI deficiency, i.e. sarcollema plus 
interstitium. In the former group all mutations were spo-
radic dominant; however, in spite of the occurrence of 
this apparently specific localization of mutated collagen 
VI, they could not define any genotype/phenotype corre-
lation. Kawahara et al.139,140 also found that in Ullrich CMD 
due to heterozygous mutations in Col6 genes collagen 
VI is preserved in the interstitium but lost in the sarco-
lemma. As in normal conditions collagen VI is particu-
larly abundant close to the cells and in intimate contact 
with basement membranes surrounding myocytes, its lack 
caused by heterozygous mutations in Col6 genes dimin-
ish the anchorage of collagen VI microfibrils to the extra-
cellular matrix. 
Finally, lampe et al.122 recently concluded that in col-
lagen VI related disorders the genotype-phenotype cor-
relation does exist and that the type and location of exon 
skipping mutation is predictive for severity and inheri-
tance. They compared the molecular data of patients with 
Ullrich CMD with de novo dominant negative heterozy-
gous splice mutations in Col6A1, Col6A2, and Col6A3, 
Ullrich CMD with recessively acting splice mutations, and 
Bethlem myopathy with heterozygous splice mutations. 
For the three types of mutations, i.e. dominant and re-
cessive Ullrich CMD as well as dominant Bethlem myo-
pathy, they discussed the different mechanisms by which 
the location of the skipped exon in relation to the mo-
lecular structure of the collagen chain and to the degree 
of interference on the collagen VI microfibrils assembly, 
strongly correlated with the clinical phenotype. There-
fore, they add new evidence to the knowledge that in last 
instance the clinical severity depends on the ability of 
mutant chains to be incorporated in the final multimeric 
structure of collagen VI microfibrillar network122.
Although rarely, Ullrich phenotype can be detected 
even in patients who do not harbor mutations in the col-
lagen VI genes and show a normal amount of collagen VI 
in the interstitium. Ishikawa et al.141 considered that these 
patients could have a primary abnormality of other not 
yet identified protein interacting with collagen VI in the 
sarcolemma causing a failure of collagen VI to anchor the 
basal lamina to the interstitium. however, according to 
okada et al.138 the possibility of mutations affecting the 
promoter regions or introns, or of overlooked mutations 
must be considered in such cases.
In conclusion, it is clear that the complex genotype-
phenotype correlations of collagen VI- related disorders 
are next to be elucidated. recently137, three novel colla-
gen VI chains, alpha-4, alpha-5, and alpha-6 were found 
in mice in or close to basement membrane. These chains 
structurally resemble the collagen VI alpha-3 chain, appar-
ently having the ability of substitute it in the constitution 
of the heterotrimers. This identification could implicate 
in new findings related to the molecular biology of Beth-
lem myopathy and Ullrich CMD.
Therapeutic perspectives
As for other types of muscular dystrophies, many re-
searches focusing on possible effective therapies have 
occurred. An animal model of human Bethlem myopa-
thy has already been described and the details about the 
composition and the role of collagen VI have been wide-
ly discussed117,142.
For at least some types of mutations, Kawahara et al.139 
suggested a therapeutic strategy based on a replacement 
therapy: in fibroblasts culture from patients with Ullrich 
CMD and Col6A1 glycine mutation, they verified that fi-
broblasts adhesion was markedly reduced but could be re-
covered by the addition of a medium with normal colla-
gen VI139. recently, Merlini et al.143 reported the results of 
an open pilot trial with oral cyclosporin A in five patients 
with collagen VI myopathies. After a month of treatment 
a new muscular biopsy showed a decrease of the mito-
chondrial and apoptotic changes in the myofibers as well 
as an increase of regenerative signs143. According to An-
gelin et al.144,145, an anomalous mitochondrial depolariza-
tion has been demonstrated in myoblasts from patients 
with Ullrich CMD, and cyclosporin A as well as intracel-
lular Ca (2+) chelators, probably, prevent such anomalous 
mitochondrial depolarization and a consequent ATP de-
pletion. Also Zou et al.146 recently reported another pos-
sible implication for future therapies. By means of immu-
nofluorescence staining and Western blot analysis in vit-
ro they found that the secretion and deposition of colla-
gen VI in the extracellular matrix depends on interstitial 
fibroblasts but not on myogenic cells146. studies on animal 
models for collagen VI related disorders may further offer 
good perspectives for therapeutic researches147,148.
disorders of glyCosylation of alpha-
dg (alpha-dystroglyCanopathies)
Pathogenesis
The alpha-dystroglycanopathies include different 
forms of dystrophies whose clinical severity varies from 
WWs that is associated with ocular abnormalities and 
CNs malformations and is not compatible with survival 
beyond the first years of life, to forms of lGMD with lat-
er onset later and pure muscular involvement. Five forms 
of CMDs are alpha-dystroglycanopathies1-7: FCMD, MeB 
disease,WWs, MDC1C and MDC1D (Table 2). FCMD, MeB 
disease and WWs form a spectrum of increasing clinical 
severity regarding muscle, eyes and brain malformation 
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and MCD1D, with only one report, is also associated to se-
vere muscular and CNs involvement. MDC1C can manifest 
pure, although severe, muscular involvement or presents 
associated clinical and radiological CNs involvement, sug-
gested by mental retardation, cerebellar cysts and white 
matter abnormalities on neuroimaging149-151. The lack of 
CNs involvement in some patients can suggest that skel-
etal muscle is more sensitive to perturbation of dystro-
glycan30. The clinical and diagnostic particularities of each 
dystroglycanopathy were discussed in Part I of this review. 
The genetic and clinical heterogeneity of dystroglycano-
pathies are remarkable and, except for FCMD is impossi-
ble to correlate a particular gene with a specific pheno-
type (Table 2). 
The pathogenic mechanism that explains the se-
vere forms of CMDs associated with CNs manifestations 
emerged in 2001 from different works16, 152-154. Brocking-
ton et al.152 identified a gene that codifies a protein of 
the fukutin family termed fukutin related protein (FKrP) 
assigning it to 19q13.3. Mutations in the FKrP gene were 
found in children with a severe form of CMD who man-
ifested inability to walk and muscle hypertrophy but no 
CNs changes and whose muscle samples showed a sec-
ondary deficiency of laminin alpha-2 immunostaining and 
a decreased expression of alpha-dystroglycan (DG). They 
named this new genotype/phenotype association as MD-
C1C and suggested that the mutations in the FKrP gene 
causing a defective glycosilation (hypoglycosilation) of al-
pha-DG would explain the basic pathologic mechanism 
in MDC1C152. hayashi et al.153 found that the highly glyco-
sylated epitope of alpha-DG was markedly deficient in 
skeletal and cardiac muscle and reduced in brain tissue 
obtained from patients with FCMD. These findings sug-
gested that also fukutin could be involved in the glyco-
sylation of alpha-DG that, when altered, could induce a 
disruption in the extracellular surface membrane of the 
muscle fiber, also influencing CNs development153. yoshi-
da et al.16 found that the MeB gene codifies a glycosyl-
transferase named PoMGnT1 that is involved in o-man-
nosyl glycosylation and, therefore, suggested that an al-
tered glycosylation could be a new pathomechanism for 
CMDs with neuronal migration disorder16. Kano et al.154 re-
ported a selective deficiency of alpha-DG in MeB patients; 
therefore, they suggested that PoMGNT1 acts on alpha-
DG and that altered glycosylation of alpha-DG is involved 
in the pathogenesis of MeB.
At last, in 2002 two works from Campbells’ research 
group at the Iowa University17,18 demonstrated that pa-
tients with MeB and FCMD, who carry mutant PoMGnT1 
and fukutin genes, respectively, had an abnormal hypo-
Table 2. Genotype/Phenotype correlations in CMDs caused by alpha-dystroglycanopathy (the most common phenotype associated to 
each gene is underlined, and the bibliography refers to the first molecular identification).
FKrP: fukutin 
related protein FKTN: fukutin PoMGnT1
PoMT1: protein
o-mannosyl transferase 1
PoMT2: protein
o-mannosyl transferase 2
glycosyiltransferase 
“like”: lArGe
lGMD2I197 FCMD199 MeB16 WWs205 WWs156 two patients 
with severe CNs 
involvement: 
MDC1D208 and WW209
MDC 1C152 WWs200 WWs50 MDC with mental retardation, 
microcephaly, structural brain 
changes, muscle hypertrophy 
and eventual myopia206
MeB171
WWs198 MeB50 lGMD2? with severe 
myopia and normal 
intelligence50,203
MeB50 MDC with microcephaly, 
severe mental deficiency, 
possible ocular changes171,172
MeB198 Myocardiopathy, 
minimal or absent  
muscle weakness, 
normal ntelligence201
MDC with brain 
malformations 
without ocular 
abnormalities204
MDC and cerebellar 
involvement50
MDC with 
cerebellar cysts151
lGMD2M202 lGMD2? mild, with normal 
intelligence and inflammatory 
changes on muscle biopsy207
MDC with variable 
cortical, cerebellar 
and pontine 
dysplasic changes149
lGMD2? with mental 
retardation50
FCMD: Fukuyama congenital muscular dystrophy; lGMD: limb girdle muscular dystrophy; MDC: muscular dystrophy, congenital; MeB: muscle-eye-brain; 
PoMGnT1: protein o-manose beta1,2-N-acetylglucosaminyltransferase; WWs: Walker-Warburg syndrome. 
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glycosilation of alpha-DG that abolished its binding with 
the ligands, laminin alpha-2, agrin, and neurexin of the ex-
tracellular matrix. The same occured in the myodystro-
phy (myd) mouse that carried a lArGe mutation and in 
the knock-out for brain-selective alpha-DG mouse. In the 
knock-out mouse they found aberrant cerebral and cere-
bellar migration probably derived from a discontinuos pial 
surface basal lamina (glia limitans); they considered that 
the aberrant migration, similar to that seen in patients 
with MeB and FCMD, was due to the lack of DG preventing 
its high-affinity binding to the extracellular matrix lamin-
in. These results identify alpha-DG as having an essential 
role in both muscle and brain development and function 
and suggested that PoMGnT1, fukutin, and lArGe may 
have a role in transferring sugars to alpha-DG, i.e. act as 
glycosyltransferases. The recognition of the involvement 
of other two glycosyltransferases, PoMT1 and PoMT2, in 
the pathogenesis of CMDs came soon after155-156. 
During the last seven years, many have discussed and 
elucidated the pathogenesis of the defective glycosyla-
tion of alpha-DG, and the particular cortical involvement 
that is observed in many of them5,711,13,15,17,18,30,33,34,36-47,157-161. It 
is supposed that other subtypes of CMD will prove to de-
pend on mutations in genes as yet unidentified but also 
involved in alpha-DG glycosylation39,45,46,48. In addition, 
from the first reports on congenital disorders of glyco-
sylation, it seemed unlikely that the glycosyltransferases 
could have a role only in glycosylation of alpha-DG and 
the importance of looking for other protein targets has 
been emphasized37,38.
The role of alpha-DG in developing brain and in neu-
ronal migration has been studied in animals models11,18,158, 
159,162,163. Zaccaria et al.162 found that in adult mice alpha-DG 
is expressed in neurons of the cerebral cortex, hippocam-
pus, olfactory bulb, basal ganglia, thalamus, hypothala-
mus, brainstem and cerebellum; in addition the astrocytes 
and their endfeet around blood vessels and the endotheli-
al cells at the blood-brain barrier, also expressed DG. Dur-
ing CNs development, alpha-DG is expressed in the ven-
tricular zone and in basement membranes, therefore par-
ticipating in neuronal proliferation, in the constitution of 
the meningeal layer and in migration process as the radi-
al glia is attached to the pial basement membrane158. In 
DG-null mice, then abnormal glycosylation of alpha-DG 
leads to different defects of neuronal migration that at 
the maximum of rupture of the pial-glial limitans, closely 
resemble the cobblestone aspect of cortex in human lis-
sencephaly type II18.
The number of glycosiltransferases involved in the gly-
cosylation of alpha-DG and their different possibilities of 
regional and developmental expression explain the spec-
trum of malformations variability and clinical severity that 
are observed in the different CMDs caused by alpha-dys-
troglycanopathies. yamamoto et al.164 analysed the expres-
sion and localization of fukutin, PoMGnT1, and PoMT1 in 
the CNs and discussed the mechanism of lesions linked 
to these three glycosyltransferase whose changes are rep-
resented by migration disorders in FCMD, MeB, and WWs. 
They observed that fukutin, PoMGnT1, and PoMT1 are ex-
pressed especially in astrocytes that compose the astro-
cytic glia limitans and therefore is involved in the forma-
tion of the basement membrane. As the latter was found 
disrupted in fetal cases of FCMD, MeB, and WWs the de-
fect in any of the three glycosyltransferases can be relat-
ed to the pathogenesis of CNs lesions. These are also ex-
pressed in immature neurons what suggests their proba-
ble involvement in neuronal migration itself. In mature 
neurons PoMGnT1 and PoMT1 are expressed but fukutin 
is rarely positive indicating that at late stages of develop-
ment PoMGnT1 and PoMT1 have a more crucial role than 
fukutin163. In addition, fukutin is expressed in pancreas, 
kidneys, bronchi, salivary gland, alimentary tract and skin 
in both fetal and adult mice, and in autopsied FCMD cas-
es it was found decreased in kidneys, lung, skin and intes-
tine163. These findings demonstrate the role of alpha-DG 
glycosylation also in non-muscle systems both during de-
velopment and in the adult; studies with the aim of clari-
fy why muscle and brain symptoms predominate in FCMD 
would be useful for better understanding the complex 
pathogenic mechanism of alpha-dystroglycanopathies163.
The wide phenotypical variation of the alpha-dystro-
glycanopathies, in particular the FKrP-related myopathies, 
has not a clear pathogenic basis. A study analysed patients 
with FKrP mutations who had also CNs alterations and 
concluded that the distribution of FKRP gene mutations 
did not allow any particular genotype/phenotype corre-
lation concerning the amount of CNs malformations149. 
Keramaris et al.24 considered that the type of missense 
point mutation could in part explain the phenotypical 
variation of FKrP gene mutations that alter the normal 
subcellular localization of FKrP protein in the Golgi ap-
paratus: the protein is kept in the endoplasmic reticulum 
and diminishes in the Golgi apparatus. Therefore, each 
mutation could act in two ways, directly altering the pre-
sumed glycosyltransferase activity and further altering the 
protein function by the mislocalization24. In patients with 
FKrP mutations, the residual expression of alpha-DG de-
tected by immunolabeling and Western blot can be corre-
lated with the clinical severity and with the type of muta-
tion168. Patients with MDC 1C who exhibit a severe pheno-
type are compound heterozygotes (one missense and one 
nonsense mutation) or have homozygous missense muta-
tions; they present absent or strongly decreased α-DG 
expression. Patients with lGMD2I at the severe end of 
the clinical spectrum (Duchenne-like) tend to present a 
marked reduction in the immunolabeling of alpha-DG and 
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are compound heterozygotes (a missense mutation and 
either another missense or a nonsense mutation) while 
patients at the milder end (later onset) generally present 
variable immunohistochemical pattern, sometimes only 
minimally changed, and in general are homozygous for the 
common C826A/leu279Ile FKrP mutation168. 
PoMT1 and PoMT2 mutations are not associated to 
the same clinical heterogeneity that is observed in the 
FKrP and in general cause classical WW or MeB pheno-
types. however, out of these classical phenotypes, dif-
ferent types and degrees of cortical and posterior fossa 
malformations have been described156, 169-174, with or with-
out eye involvement; mental retardation, and calf as well 
as thigh enlargement has also been related170,171. yanagisa-
wa et col172 hypothesized that patients with PoMT1 and 
PoMT2 mutations could share the same phenotype be-
cause, according to Manya et al.21, both glycosyltransferas-
es form a heterodimeric complex that is responsible for 
the catalysis of the first step in O-mannosyl glycan synthe-
sis. Messina et al.175 emphasized that PoMT1 and PoMT2 
mutations have a wider clinical spectrum than initially 
thought and that, excluding MeB and WWs phenotypes, 
mutations causing frameshifts and stop codons were asso-
ciated to the most severe phenotypes with predominant 
cerebellar hypoplasia commonly found. Godfrey et al.50 
analysed eight patients with PoMT1 mutations and nine 
with PoMT2 mutations and suggested that POMT1 and 
POMT2 mutations do not seem to manifest a hierarchical 
involvement of muscle and brain, being associated with 
significant central nervous system involvement even in pa-
tients with relatively mild weakness and who remain am-
bulant (lGMD2K). In this large revision about alpha-dys-
troglycanopathies not related to FKrP mutations Godfrey 
et al.50 found a broad correlation between the amount of 
depleted glycosylated epitope and phenotypic severity. 
recently another study165 demonstrated a good cor-
relation between the clinical phenotype and the amount 
of glycosylated alpha-DG with the most severe cases be-
ing associated to a lack or marked reduction of glycosylat-
ed alpha-DG. however, this correlation was strong in pa-
tients with PoMT1, PoMT2 and PoMGnT1 mutations, but 
not consistent in patients whose mutations had occurred 
in fukutin and FKrP genes. 
The amount of dystroglycan hypoglycosylation is de-
tected utilizing two monoclonal antibodies (IIh6 and VIA41) 
that recognize only the functional glycosylated epitope 
of alpha-DG30; further immunohistochemical studies will 
be useful for identifying all the glycan structures induced 
by glycosyltransferases, in particular lArGe activity30. 
Considering all the alpha-dystroglycanopathies that 
have already been supposed by means of hypoglycosila-
tion on the immunohistochemical analysis of muscle bi-
opsies, Muntoni et al.5 pointed to a rate of confirmed mo-
lecular diagnosis around 65% of the cases, suggesting that 
more genes have yet to be identified. The same is clearly 
demonstrated by the work from Godfrey et al.50 that de-
scribed many patients who had a phenotype suffesting al-
pha-dystroglycanopathy but no mutations in any of the 
six glycosyltransferases already identified. Therefore, they 
concluded that undefined, genes are likely to be involved 
in the pathogenesis of the dystroglycanopathies and that 
the identification of these genes may provide additional 
information on the pathway of glycosylation of alpha-DG.
other great evidence pointing to the probability of 
the existence of more genes codifying glycosyltransferas-
es not yet identified comes from the molecular studies 
from patients with WWs. In spite of its worldwide dis-
tribution and therefore the good availability of patients’ 
DNA for genomic analysis, only one third of the cases has 
been associated to mutations in one of the six genes in-
volved in the o-manosylation pathways50,166,167. It is sup-
posed then that additional loci are going to be identi-
fied soon30,167. 
Finally, Moore and hewitt30 recently hypothesized 
that genetic variation between patients for other genes 
that might have compensatory functions could contrib-
ute to this clinical heterogeneity.
Therapeutic perspectives
Glycobiology of o-mannosyl glycans is a broad and 
open field of research that can favor the understanding 
of the pathogenesis and consequently the advent of a 
possible thearapeutic strategy for the alpha-dystrogly-
canopathies. The researches about the long-term poten-
tial of glycotherapies for CMD have begun with the first 
reports about the defective alpha-DG glycosylation as a 
new pathogenic mechanism for some subtypes of7,11,13,15,32-
34,36-48,157,176,177. The central point of these researches is that 
the overexpression of lArGe promotes the attachement 
of glycans to alpha-DG, therefore restoring its ligand-
binding function178. 
Barresi et al.178 demonstrated that in large(myd)mice 
overexpression of lArGe leads to a recovery of alpha-
DG function as a receptor and ameliorates the dystrophic 
phenotype; in normal mice induces the synthesis of gly-
can-enriched alpha-DG with high affinity for extracellular 
ligands. They also demonstrated that in cell lines derived 
from patients with WWs and MeB (PoMT1, PoMGnT1 or 
fukutin mutations) as well as in transfected cell cultures 
from all cell lines, gene transfer of lArGe restores the 
laminin-binding activity of alpha-DG and results in hy-
perglycosylation of alpha-DG; these data indicate that, at 
least in this experimental over-expression system, lArGe 
may act in a different glycosylation pathway178. Therefore, 
up regulation of this gene might represent a therapeutic 
approach for the muscular dystrophies caused by defects 
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of alpha-DG glycosyilation178. The large myd mouse is an 
excellent and complete model for glycosylation-deficient 
CMDs as displays skeletal, cardiac and tongue muscle pa-
thology, defective retinal transmission, and neuronal mi-
gration defects179.
The lArGe homologue, glycosyltransferase-like 1B 
(GylTl1B), named lArGe2, shows similar sequence and 
genomic organization and as lArGe-1 is localized in the 
Golgi apparatus, what suggests its function in glycosy-
lation29. since transient overexpression of lArGe2 in 
mouse myoblast cell line increased alpha-DG glycosyla-
tion and its affinity to bind laminin, Grewal et al.29 hy-
pothesized that partial functional redundancy might oc-
cur between lArGe 1 and lArGe 2; therefore, the latter 
should be considered an additional potential therapeutic 
target. The details about the enzymatic activity of lArGe 
and lArGe 2 and the identification of the glycan struc-
tures that both induce remain undefined30. In addition, it 
is probable that lArGe 2 overexpression could compen-
sate not only lArGe deficiency as also that of other gly-
cosyltransferases177. Indeed, it is expected that lArGe 2 
could be a candidate gene for an eventual non CMD-like 
genetic disease, as lArGe 2 has very low expression in 
muscle and brain30.
however, the CMDs caused by alpha-dystroglycanop-
athies constitute a therapeutic challenge because any in-
tervention might be early, even prenatally and would need 
to reach multiple tissues. In addition to the potentially 
therapeutic overexpression of lArGe 1 and 2, other pos-
sible strategies have been discussed37,38,40,178,180,181: to obtain 
synthetic donors of sugars that could serve as glycan an-
alogues; to carry on enzyme replacement via gene ther-
apy, and to provide ectopic expression or upregulation 
of other glycosyltransferases that might compensate the 
loss of function of that altered by the mutation. A similar 
mechanism has been tested in a mouse model of Duch-
enne muscular dystrophy in which the dystrophic pro-
cess was inhibited by the overexpression of Galgt2, an-
other glycosyltransferase not implicated in CMD48,176,182. 
This promoted the synthesis of a form of a-DG that was 
followed by the recruitment of utrophin at the sarcolle-
ma, therefore restoring its stability. recent works point-
ed to the fact that potential therapeutic strategies first-
ly depend on the complete elucidation of the molecular 
mechanism that is involved in the formation of DG struc-
ture, ligands and function, not only in muscles but also in 
non-neuromuscular tissues48,176. 
The glycosylation itself is poorly understood and 
many points have to be considered. According to scian-
dra et al.176, there might be that glycosyltransferases tar-
get other, unidentified, molecules that, hypoglycosylated, 
could also contribute to the pathogenesis of the alpha-
dystroglycanopathies. They also stressed the importance 
of better analyzing the interaction between both, alpha 
and beta subunits, for DG function176.
Brancaccio157 discussed the possibility of the existence 
of a primary dystroglycanopathy, and hypoglycosylated, or 
even hyperglycosylated alpha-DG molecules also involved 
either in functional or pathological status; as the other au-
thors above reported, he also emphasized that a possible 
therapeutic option could come from the compensatory 
glycosylation function of paralogue glycosyltransferases157.
Besides the therapeutic perspectives, in the topic 
correspondent to each subtype of CMD, we have already 
mentioned the genetic animal models, in general mice 
that have been studied in the researches on laminin al-
pha-2 deficient CMD, collagen VI related disorders, and 
many different types of alpha-dystroglycanopathies. oth-
er, unusual, animal models have been utilized. In zebrafish, 
all the six identified or putative glycosyltransferases im-
plicated in the pathogenic mechanism of the human mus-
cular dystrophies were found to have similar patterns and 
expression than in patients, inclusively throughout ear-
ly development. Therefore the zebrafish can be a useful 
model system for future researches183,184. Another experi-
mental model for muscular dystrophies associated to dis-
orders of alpha-DG glycosylation has also been found in 
mutant Drosophilas185 . The experimental studies in ani-
mal models provide new perspectives for clarifying the 
pathogenic mechanism of the CMDs and for testing po-
tential therapeutic strategies. Unfortunately, until the mo-
ment the possibility of transferring some of the good re-
sults obtained in animal experiments to humans, in vivo, 
has to be considered with moderate optimism. 
rigid spine Cmd
Pathogenesis
rigid spine syndrome CMD is characterized by marked 
limitation in the flexion of the spine, gradual develop-
ment of scoliosis leading to reduced respiratory vital ca-
pacity and respiratory failure as well as joints contrac-
tures. In 2001, Moghadaszadeh et al.9 identified the sePN1 
gene and several mutations resulting in rigid spine CMD, 
suggesting that selenoprotein N can be involved in redox 
reactions into the cell, protecting it from oxidant dam-
age. Petit et al.186 demonstrated that sePN1 is a glycopro-
tein-localized within the endoplasmic reticulum that is 
more abundant in human fetal tissues than in adult ones, 
including skeletal muscle. Although it is not a muscle spe-
cific protein and it is ubiquitously expressed, its expres-
sion is particularly marked in cultured myoblasts and de-
creases in differentiating myotubes, suggesting a role in 
early development and in cell proliferation and regener-
ation186. In zebrafish embryos deficient for sePN, muscle 
organization and myofibrils architecture are altered dur-
ing early development187.
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In 2002, Ferreiro et al.188 concluded that rigid spine 
CMD and the most severe form of classic multiminicore 
disease are different phenotypes associated with muta-
tions in sePN1 gene. later, they189 also demonstrated ho-
mozygous sePN1 deletion in patients with CMD with Mal-
lory body-like inclusions. Finally Clarke et al.190 described 
sePN1mutations in two sisters with a diagnosis of typical 
congenital fiber-type disproportion without minicore le-
sions or dystrophic changes. Therefore the spectrum of 
selenoprotein-related disorders includes rigid spine CMD, 
multiminicore myopathy, desmin-related myopathy with 
Mallory body-like inclusions and congenital fiber-type 
disproportion. rederstorff et al.191 confirmed the impor-
tance of selenium-containing proteins in muscle forma-
tion, maintenance and repair and attested that in patients 
with selenoprotein-related disorders most of mutations 
are nonsense mutations and deletions, likely to induce a 
loss of function.
As multiminicore myopathy is also caused by muta-
tions in ryr1 gene that codifies the major component 
of the ryanodine receptor intracellular calcium release 
channel192,193, the relations ships between sePN1 and ryr1 
could explain this overlapping spectrum of congenital my-
opathies194. In the zebrafish embryo, Jurynec et al.194 dem-
onstrated that the two proteins participate of the same 
cellular differentiation events and of the regulation of 
calcium fluxes. sePN1 acts as a modifier of the ryr chan-
nel. In the absence of sePN1, ryr channels lose their nor-
mal sensitivity to redox conditions. This finding explains 
because mutations affecting either factor lead to simi-
lar diseases194. lescure et al.195 recently stressed the im-
portance of also studying the correlation between seP-
NI gene and protein and other genes involved in similar 
phenotypes, like desmin, alpha-actin and different sele-
noproteins acting in muscles and myocardium. In addi-
tion, the molecular function of sePN and the role of the 
selenocystein (sec) insertion that not only integrates the 
protein itself but also controls its mrNA quality needs to 
be further analysed195. 
Therapeutic perspectives
recently rederstorff et al.196 reported a patient with 
a homozygous point mutation at the selenocystein (sec) 
codon (c.G1385A) that converted the normal codon UGA 
to UAA, therefore preventing synthesis of a full-length 
active sePN protein. Then, they195 “engineered a mutant 
trNAsec gene carrying a point mutation in the anticodon, 
thereby restoring the base-pair complementarity with the 
sePN1 mutated codon; in patient-derived primary fibro-
blasts the corrector trNAsec gene allowed read-through of 
the UAA stop codon, thus enabling synthesis of the full-
length sePN protein”196. This is the first attempt of a thera-
peutic strategy for rigid spine CMD and other sePN related 
disorders, using a mutation-specific approach. Considering 
the highly specific molecular context of sePN1 mutations, 
the authors195 discuss in details and emphasize the effi-
ciency and technical advantages of this alternative strat-
egy in relation to conventional gene-therapy strategies. 
In conclusion, the advances in the field of molecu-
lar genetics, cell biology and biochemistry have been the 
source of a better knowledge on the pathogenic mecha-
nisms involved in the CMDs. however, the development 
of effective therapies is still at a preclinical stage, except 
for an attempt of treating patients with Ullrich pheno-
type with cyclosporin A143.
Unfortunately, the induction of a functional protein by 
gene modification, cell therapy or pharmacological agents 
has been a long and difficult task. The effective thera-
py is coming but employing it in large-scale clinical tri-
als constitutes a challenge that is much greater in unde-
veloped countries. 
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